We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Uroplakin 3A derived peptide vaccination reduced tumor growth in bladder cancer mice model.
- Authors
Izgi, Kenan; Iskender, Banu; Canatan, Halit; Ulusoy, Hasan Basri; Sonmez, Mehmet Fatih
- Abstract
Introduction: Uroplakin 3A (UPK3A) is a well-chosen target to develop autoimmune response against bladder cancer since the antigen is also expressed in bladder tumor. In previous study, we developed T-cell mediated bladder specific autoimmunity by targeting bladder-specific UPK3A protein. In this study, we analyzed immune response in BALB/c mice after immunization with UPK3A 65-84 peptide its ability to reduce bladder tumor growth. Material and Method: Keyhole Limpet Hemocyanin (KLH) conjugated peptide was used with either CFA (Complete Freund's Adjuvant) or CpG (Cytosine-phosphate-guanine) as effective adjuvants. Bladder cancer model in mice was formed after OH-BBN administration to the mice for 12 weeks. Immune response evoked by UPK3A 65-84 peptide with different adjuvants was compared with the detection of immune cells by flow cytometer. The apoptosis induction capability of this vaccination in tumor tissue was also analyzed. Results and Discussion: We observed that CpG combined with KLH conjugated peptide (UPK3A 65-84) promotes robust immune response via activation of higher immune cells (CD4+ T cell, CD8+ T cells, NK cells CD11b) than KLH conjugated peptide with CFA. CFA or CpG as an adjuvant combined with KLH conjugated peptide significantly reduced tumor growth compared to control groups in mice with bladder. Conclusion: This peptide is well-chosen target for the development of bladder cancer immunotherapy. Accordingly, UPK3A 65-84 peptide vaccination could provide safe and effective protection against the development of bladder cancer.
- Subjects
UROPLAKINS; TUMOR growth; BLADDER cancer; LABORATORY mice; T cells
- Publication
Turkish Journal of Immunology, 2016, Vol 4, p21
- ISSN
1301-109X
- Publication type
Article